NIH Shopping Peptide Eyedrops to Save Your Vision
Published Date: 7/24/2026
Notice
Summary
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Potential New Treatment for Retinal Degeneration
Researchers developed a 17-amino-acid PEDF peptide (17-mer [H105A]) that showed potent protective effects on photoreceptors in in vivo mouse models. This peptide could be developed as an eyedrop or AAV2 gene-delivery therapy to prevent or slow photoreceptor degeneration in inherited retinal diseases like retinitis pigmentosa (affecting over 100,000 people in the U.S.) and in age-related macular degeneration.
NIH Offering PEDF Licensing Opportunity
The National Eye Institute (NEI) is seeking partners or licensees to co-develop a Pigment Epithelium-Derived Factor (PEDF) peptide therapy using either an AAV2-based delivery system or an eyedrop formulation. The technology is offered with NIH Reference Number E-028-2023 and is available for licensing and co-development now.
Therapy Still at Pre-Clinical Stage
The PEDF peptide technology and delivery approaches are at the pre-clinical development stage (in vivo validation). That means the therapy is not yet approved or available for clinical use while further development is pursued.
Developer Advantage: AAV2 Pathway Similarity
NEI notes the AAV2 vector approach is identical to Luxturna, an FDA-approved retinal therapy, suggesting a partially established regulatory path for developers pursuing an AAV2 delivery route. The notice highlights competitive advantages such as favorable safety profile and lower production costs compared with biologics.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-14979, Cboe Clear U.S., LLC; Notice of Filing of an Application, as Amended, for Temporary Registration as a Clearing Agency Under Section 17A of the Securities Exchange Act of 1934
Cboe Clear U.S., LLC wants to become a temporary official clearing agency to handle special financial contracts called binary options. This change affects traders and companies dealing with these contracts by adding a trusted middleman to make sure trades settle smoothly. The SEC is reviewing the application and asking for public feedback before making a final decision.
Next: 2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.